Language:

Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma

Annals of oncology, 2012-08, Vol.23 (8), p.2108-2114 [Peer Reviewed Journal]

2012 European Society for Medical Oncology ;2015 INIST-CNRS ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdr586 ;PMID: 22228449

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma
Author: Lee, J.-L. ; Ahn, J.-H. ; Lim, H.Y. ; Park, S.H. ; Lee, S.H. ; Kim, T.M. ; Lee, D.-H. ; Cho, Y.M. ; Song, C. ; Hong, J.H. ; Kim, C.-S. ; Ahn, H.
Subjects: Adolescent ; Adult ; Aged ; Antineoplastic agents ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Carcinoma, Renal Cell - drug therapy ; Carcinoma, Renal Cell - pathology ; chromophobe type renal cell carcinoma ; Female ; Humans ; Indoles - adverse effects ; Indoles - therapeutic use ; Kidney Neoplasms - drug therapy ; Kidney Neoplasms - pathology ; Kidneys ; Male ; Medical sciences ; Middle Aged ; Neoplasm Metastasis ; Nephrology. Urinary tract diseases ; papillary type renal cell carcinoma ; Pharmacology. Drug treatments ; phase II ; Prospective Studies ; Pyrroles - adverse effects ; Pyrroles - therapeutic use ; Sunitinib ; Tumors of the urinary system ; Young Adult
Is Part Of: Annals of oncology, 2012-08, Vol.23 (8), p.2108-2114
Description: Retrospective and molecular biologic data suggest that sunitinib may be effective in patients with non-clear cell renal cell carcinoma (nccRCC). Eligibility criteria included advanced nccRCC except for collecting duct carcinoma and sarcomatoid carcinoma without identifiable renal cell carcinoma subtypes. Patients were treated with 50 mg/day oral sunitinib for 4 weeks, followed by 2 weeks of rest. The primary end point was overall response rate (RR). Thirty-one eligible patients were enrolled. Twenty-four patients (77%) had prior nephrectomy. By Memorial Sloan-Kettering Cancer Center criteria, 8 patients (26%) had poor risk and 14 (45%) had intermediate risk. Twenty-two patients had papillary renal cell carcinoma (RCC), and three had chromophobe RCC. Eleven patients had partial response with a RR of 36% (95% confidence interval (CI) 19% to 52%) and an additional 17 patients (55%) had stable disease. Median duration of response was 12.7 months (95% CI 6.3–19.1 months), and median progression-free survival was 6.4 months (95% CI 4.2–8.6 months). At a median follow-up duration of 18.7 months (95% CI 13.7–23.7 months), 13 patients (42%) had died, resulting in an estimated median survival of 25.6 months (95% CI 8.4–42.9 months). Toxicity profiles were commensurate with prior reports. Sunitinib has promising activity in patients with nccRCC (NCT01219751).
Publisher: Oxford: Elsevier Ltd
Language: English
Identifier: ISSN: 0923-7534
EISSN: 1569-8041
DOI: 10.1093/annonc/mdr586
PMID: 22228449
Source: Geneva Foundation Free Medical Journals at publisher websites
MEDLINE
Alma/SFX Local Collection

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma

2012 European Society for Medical Oncology ;2015 INIST-CNRS ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdr586 ;PMID: 22228449

Searching Remote Databases, Please Wait